| 000 | 01884 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513233502.0 | ||
| 264 | 0 | _c20010621 | |
| 008 | 200106s 0 0 eng d | ||
| 022 | _a0022-1767 | ||
| 024 | 7 |
_a10.4049/jimmunol.166.7.4334 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDe Benedetti, F | |
| 245 | 0 | 0 |
_aIn vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6-transgenic mice with a hIL-6 receptor antagonist. _h[electronic resource] |
| 260 |
_bJournal of immunology (Baltimore, Md. : 1950) _cApr 2001 |
||
| 300 |
_a4334-40 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAmino Acid Substitution _xgenetics |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnimals, Newborn _xgenetics |
| 650 | 0 | 4 |
_aAntibody Formation _xgenetics |
| 650 | 0 | 4 |
_aDown-Regulation _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGrowth Disorders _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunity, Maternally-Acquired |
| 650 | 0 | 4 | _aImmunization, Secondary |
| 650 | 0 | 4 |
_aInsulin-Like Growth Factor I _xmetabolism |
| 650 | 0 | 4 |
_aInterleukin-6 _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 |
_aMice, Transgenic _ximmunology |
| 650 | 0 | 4 |
_aPhosphopyruvate Hydratase _xgenetics |
| 650 | 0 | 4 |
_aReceptors, Interleukin-6 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 650 | 0 | 4 |
_aVaccination _xmethods |
| 700 | 1 | _aPignatti, P | |
| 700 | 1 | _aVivarelli, M | |
| 700 | 1 | _aMeazza, C | |
| 700 | 1 | _aCiliberto, G | |
| 700 | 1 | _aSavino, R | |
| 700 | 1 | _aMartini, A | |
| 773 | 0 |
_tJournal of immunology (Baltimore, Md. : 1950) _gvol. 166 _gno. 7 _gp. 4334-40 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4049/jimmunol.166.7.4334 _zAvailable from publisher's website |
| 999 |
_c11191401 _d11191401 |
||